Sutton S Scott
S. Scott Sutton is a professor in the Department of Clinical Pharmacy and Outcomes Sciences in the South Carolina College of Pharmacy at the University of South Carolina in Columbia, S.C. The author has disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2017 Jan;30(1):11-13. doi: 10.1097/01.JAA.0000511033.34198.95.
The FDA has updated azithromycin package labeling to include the risk of prolonged cardiac repolarization and QT prolongation, which increase the possibility of cardiac dysrhythmias and torsades de pointes, especially in older adults. The update was initiated by a study that found an increased risk of death in patients taking azithromycin compared with those taking amoxicillin. However, cardiovascular results of other azithromycin studies have demonstrated discordant results, and more research is needed. In the meantime, providers should recognize that azithromycin has a role in the management of bacterial infections and should prescribe the antibiotic when warranted.
美国食品药品监督管理局（FDA）已更新阿奇霉素的药品标签，以纳入心脏复极化延长和QT间期延长的风险，这会增加心律失常和尖端扭转型室速的可能性，尤其是在老年人中。此次更新是由一项研究引发的，该研究发现服用阿奇霉素的患者比服用阿莫西林的患者死亡风险更高。然而，其他阿奇霉素研究的心血管结果显示出不一致的结果，因此还需要更多的研究。与此同时，医疗服务提供者应认识到阿奇霉素在细菌感染治疗中具有一定作用，应在有必要时开具这种抗生素。
